- Ticker
- ADAP
- Price
- 1.08
- Stock movement up
- +0.04 (3.85%)
- Company name
- Adaptimmune Therapeutics Plc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 178.53M
- Ent value
- 317.53M
- Price/Sales
- 6.58
- Price/Book
- 2.18
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -35.33%
- 3 year return
- -54.40%
- 5 year return
- -39.10%
- 10 year return
- -
Last updated: 2023-06-06
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
June 1, 2023
iO Charts is a Seeking Alpha partner
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor RelationsAdrian Rawcliffe - Chief...
May 12, 2023
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADAP does not pay dividends or no data was received
Loading...
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.58 |
| Price to Book | 2.18 |
| EV to Sales | 11.70 |
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
May 12, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
May 11, 2023
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 165.30M |
| EPS (TTM) | -0.17 |
| FCF per share (TTM) | -0.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 27.15M |
| Gross profit (TTM) | 27.15M |
| Operating income (TTM) | -136.72M |
| Net income (TTM) | -165.46M |
| EPS (TTM) | -0.17 |
| EPS (1y forward) | -0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -503.62% |
| Profit margin (TTM) | -609.46% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 108.03M |
| Net receivables | 7.43M |
| Total current assets | 255.37M |
| Goodwill | 0.00 |
| Intangible assets | 442.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 328.92M |
| Accounts payable | 4.75M |
| Short/Current long term debt | 23.08M |
| Total current liabilities | 64.50M |
| Total liabilities | 247.04M |
| Shareholder's equity | 81.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -141.77M |
| Capital expenditures (TTM) | 29.50M |
| Free cash flow (TTM) | -171.26M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -202.08% |
| Return on Assets | -50.30% |
| Return on Invested Capital | -195.56% |
| Cash Return on Invested Capital | -202.43% |
Loading...
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.05 |
| Daily high | 1.12 |
| Daily low | 0.99 |
| Daily Volume | 2.36M |
| All-time high | 21.12 |
| 1y analyst estimate | 5.86 |
| Beta | 2.21 |
| EPS (TTM) | -0.17 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 2 Aug 2023 |
Downside potential
Loading...
Downside potential data
| ADAP | S&P500 | |
| Current price drop from All-time high | -94.89% | -10.40% |
| Highest price drop | -96.57% | -56.47% |
| Date of highest drop | 15 Nov 2019 | 9 Mar 2009 |
| Avg drop from high | -71.49% | -11.53% |
| Avg time to new high | 407 days | 13 days |
| Max time to new high | 2008 days | 1805 days |
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
May 11, 2023
iO Charts is a Seeking Alpha partner
ADAP is swapping 1.5117 of its shares for every TCRR share. Click to read how shareholders can lock in a big gain once the deal closes.
April 21, 2023
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
178.53M
Marketcap category
Small-cap
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees
534
Website
Investor relations
-
SEC filings
CEO
Adrian Rawcliffe
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
April 18, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
April 11, 2023
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Adaptimmune is down after merging with TCR2, while TCR2 is up. Read more to see why the merger with TCRR stock looks like a smart deal for ADAP stock.
March 26, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 23, 2023
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor RelationsAdrian Rawcliffe - Chief...
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 3, 2023
TCR² Therapeutics has refocused its pipeline to a few specific clinical products. Read more to see why I'm bullish on TCRR stock.
February 15, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
January 3, 2023
Adaptimmune has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline. Read our analysis of ADAP stock.
December 9, 2022
iO Charts is a Seeking Alpha partnerNext page